Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
Kenrie P. Y. Hui, John Chi Wang Ho, Man Chun Cheung, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 715-720
Open Access | Times Cited: 745

Showing 1-25 of 745 citing articles:

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
Tommy Nyberg, Neil M. Ferguson, Sophie Nash, et al.
The Lancet (2022) Vol. 399, Iss. 10332, pp. 1303-1312
Open Access | Times Cited: 1150
SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 937
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
Cristina Menni, Ana M. Valdes, Lorenzo Polidori, et al.
The Lancet (2022) Vol. 399, Iss. 10335, pp. 1618-1624
Open Access | Times Cited: 782
The evolution of SARS-CoV-2
Peter V. Markov, Mahan Ghafari, Martin Beer, et al.
Nature Reviews Microbiology (2023) Vol. 21, Iss. 6, pp. 361-379
Open Access | Times Cited: 724
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
Hung Fu Tseng, Bradley K. Ackerson, Yi Luo, et al.
Nature Medicine (2022) Vol. 28, Iss. 5, pp. 1063-1071
Open Access | Times Cited: 491
SARS-CoV-2 Omicron variant: recent progress and future perspectives
Yao Fan, Xiang Li, Lei Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 471
Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2
Olha Puhach, Kenneth Adea, Nicolas Hulo, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1491-1500
Open Access | Times Cited: 323
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California
Joseph A. Lewnard, Vennis Hong, Manish M. Patel, et al.
Nature Medicine (2022) Vol. 28, Iss. 9, pp. 1933-1943
Open Access | Times Cited: 321
Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure
Catherine J. Reynolds, Corinna Pade, Joseph M. Gibbons, et al.
Science (2022) Vol. 377, Iss. 6603
Open Access | Times Cited: 314
The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein
Thomas P. Peacock, Jonathan C. Brown, Jie Zhou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 253
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
Izumi Kimura, Daichi Yamasoba, Tomokazu Tamura, et al.
Cell (2022) Vol. 185, Iss. 21, pp. 3992-4007.e16
Open Access | Times Cited: 238
A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
Srijan Chatterjee, Manojit Bhattacharya, Sagnik Nag, et al.
Viruses (2023) Vol. 15, Iss. 1, pp. 167-167
Open Access | Times Cited: 190
Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events
Junxian Ou, Wendong Lan, Xiaowei Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 187
Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study
Waasila Jassat, Salim S. Abdool Karim, Caroline Mudara, et al.
The Lancet Global Health (2022) Vol. 10, Iss. 7, pp. e961-e969
Open Access | Times Cited: 184
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters
Shuofeng Yuan, Zi‐Wei Ye, Ronghui Liang, et al.
Science (2022) Vol. 377, Iss. 6604, pp. 428-433
Closed Access | Times Cited: 166
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
Venice Servellita, Abdullah M. Syed, Mary Kate Morris, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1539-1548.e5
Open Access | Times Cited: 159
Omicron: increased transmissibility and decreased pathogenicity
G. A. Balint, Barbara Vörös-Horváth, Aleksandar Széchenyi
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 154
Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods — United States, April 2020–June 2022
Stacey Adjei, Kai Hong, Noelle‐Angelique Molinari, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 37, pp. 1182-1189
Open Access | Times Cited: 153
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
Panke Qu, Julia N. Faraone, John P. Evans, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112443-112443
Open Access | Times Cited: 144
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, et al.
EBioMedicine (2022) Vol. 84, pp. 104270-104270
Open Access | Times Cited: 138
Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England
Matthew Whitaker, Joshua Elliott, Barbara Bodinier, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 113
SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development
Danyi Ao, Tianxia Lan, Xuemei He, et al.
MedComm (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 105
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark
Christian Holm Hansen, Nikolaj Ulrik Friis, Peter Bager, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 2, pp. 167-176
Open Access | Times Cited: 98
Page 1 - Next Page

Scroll to top